Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
Chemotherapy probably leads to higher progression‐free survival compared with biological therapy (moderate certainty).
It is very uncertain whether chemmotherapy combined with biological therapy changes progression‐free survival compared with chemotherapy (very low certainty).
Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes progression‐free survival compared with BSC (very low certainty).
Summary of findings table (subcomparison 2): second‐line… may leads to lower progression‐free survival compared with control intervention alone (low certainty).
The review found no eligible studies for this question.
Summary of findings table: chemotherapy or targeted therapy agent(s)… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).
Summary of findings table (subcomparison 4): targeted therapy agent… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).
Chemotherapy showed no clear difference in progression‐free survival (non‐taxane monotherapy vs taxane… compared with chemotherapy (low certainty).